Fengyun Wang, n/a
ICU Doctor
Zhongnan Hospital of Wuhan University, United States
Disclosure information not submitted.
Yiming Li
MS
Zhongnan Hospital of Wuhan University
Wuhan, United States
Disclosure information not submitted.
Zhiyong Peng
Prof.
Zhongnan Hospital of Wuhan University
Wuhan, Pennsylvania, United States
Disclosure information not submitted.
Title: The safety and efficacy of mesenchymal stromal cells for treating ARDS - a meta-analysis of RCTs.
Objectives: Mesenchymal stromal cells (MSC) have shown potential efficacy in many animal trials of ARDS; additionally, in recent years, a few clinical trials of MSC for the treatment of ARDS have been reported. The purpose of this study is to evaluate the safety and efficacy of MSC in ARDS via a meta-analysis of randomized controlled trials (RCTs).
Design: A meta-analysis of RCTs of MSC as a therapy for ARDS was conducted. Searches, with no language restriction and done according to the “PICO” principle, were conducted on Pubmed to retrieve any clinical literature pertaining to MSC for ARDS.
Results: A total of 4 RCTs, which evaluated MSC versus control (standard treatment) for treating ARDS, enrolling a total of 136 cases, met the inclusion criteria and appear in this meta-analysis. This present meta-analysis indicated that there was no difference in terms of adverse envents between MSC and standard treatment for ARDS (OR = 1.11, 95% CI [0.27, 4.63], P = 0.88); that, in comparison with standard treatment, MSC could reduce the mortality of ARDS (OR = 0.37, 95% CI [0.15, 0.86], P = 0.02).
Conclusion: Based on the results of our meta-analysis, the safety of MSC was demonstrated to be non-inferior to that of standard treatment, and that MSC may reduce the mortality rate of moderate and severe ARDS. In view of the small sample of the meta-analyses and the non-negligible heterogeneity among the included studies, more high-quality, large-scale clinical trials are required.